Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Protein and Peptide Letters
  4. Volume 31, Issue 9
  5. Article
Volume 31, Issue 9
  • ISSN: 0929-8665
  • E-ISSN: 1875-5305

Abstract

Objective

The aim was to investigate the potential relationship between Vav1 protein and prognosis in patients with hepatocellular carcinoma (HCC).

Methods

Samples were collected from 96 patients with HCC. For each patient, cancerous tissue and adjacent non-cancerous tissue were obtained. The Vav1 expression levels in these tissues were determined using immunohistochemistry. Chi-square and Fisher's exact tests were used to analyse the associations between Vav1 expression and clinicopathological characteristics. Kaplan–Meier analysis was used to assess the relationship between Vav1 expression and 5-year overall survival (OS).

Results

The expression level of Vav1 protein in primary tumour samples (64.46%; 59/96) was higher (33.33%; 32/96; 0.001). Moreover, the high expression rate of Vav1 was correlated with tumour differentiation, TNM stage, and tumour recurrence (0.05). Univariate and multivariate Cox analysis further demonstrated that tumour differentiation, TNM stage, vascular invasion, tumour recurrence and Vav1 expression were independent prognostic factors for 5-year OS. Notably, follow-up analysis determined that patients with HCC with higher Vav1 expression levels have lower survival rates (0.05).

Conclusion

Vav1 may serve as a promising molecular prognostic biomarker for patients diagnosed with HCC.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ppl/10.2174/0109298665330781240830042601
2024-09-19
2025-03-07

  • From This Site

    /content/journals/ppl/10.2174/0109298665330781240830042601
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.2166033538338
     [Google Scholar]
  2. ShiJ.F. CaoM. WangY. BaiF.Z. LeiL. PengJ. FelettoE. CanfellK. QuC. ChenW. Is it possible to halve the incidence of liver cancer in China by 2050?Int. J. Cancer202114851051106510.1002/ijc.3331332997794
     [Google Scholar]
  3. YangJ.D. HainautP. GoresG.J. AmadouA. PlymothA. RobertsL.R. A global view of hepatocellular carcinoma: trends, risk, prevention and management.Nat. Rev. Gastroenterol. Hepatol.2019161058960410.1038/s41575‑019‑0186‑y31439937
     [Google Scholar]
  4. TayobN. KanwalF. AlsarrajA. HernaezR. El-SeragH.B. The performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma (HCC): A phase 3 biomarker study in the United States.Clin. Gastroenterol. Hepatol.2023212415423.e410.1016/j.cgh.2022.01.04735124267
     [Google Scholar]
  5. ShalomB. FaragoM. SalaymehY. SebbanS. RislingM. PikarskyE. KatzavS. Vav1 accelerates Ras-driven lung cancer and modulates its tumor microenvironment.Cell. Signal.20229711039510.1016/j.cellsig.2022.11039535752351
     [Google Scholar]
  6. ShalomB. FaragoM. SalaymehY. SebbanS. PikarskyE. KatzavS. Vav1 promotes B-cell lymphoma development.Cells202211694910.3390/cells1106094935326399
     [Google Scholar]
  7. ShalomB. SalaymehY. RislingM. KatzavS. Unraveling the oncogenic potential of VAV1 in human cancer: Lessons from mouse models.Cells2023129127610.3390/cells1209127637174676
     [Google Scholar]
  8. QiuJ. GuoJ. LiuL. LiuX. SunX. ChenH. Vav1 promotes inflammation and neuronal apoptosis in cerebral ischemia/reperfusion injury by upregulating microglial and NLRP3 inflammasome activation.Neural Regen. Res.202318112436244210.4103/1673‑5374.37136837282474
     [Google Scholar]
  9. GrassilliS. BrugnoliF. CairoS. BianchiN. JuddeJ.G. BertagnoloV. Vav1 selectively down-regulates Akt2 through miR-29b in certain breast tumors with triple negative phenotype.J. Pers. Med.202212699310.3390/jpm1206099335743776
     [Google Scholar]
  10. FukumotoK. Sakata-YanagimotoM. FujisawaM. SakamotoT. MiyoshiH. SueharaY. NguyenT.B. SumaS. YanagimotoS. ShiraishiY. ChibaK. BouskaA. KataokaK. OgawaS. IqbalJ. OhshimaK. ChibaS. VAV1 mutations contribute to development of T-cell neoplasms in mice.Blood2020136263018303210.1182/blood.202000651332992343
     [Google Scholar]
  11. Robles-ValeroJ. Fernández-NevadoL. Lorenzo-MartínL.F. CuadradoM. Fernández-PisoneroI. Rodríguez-FdezS. Astorga-SimónE.N. AbadA. CalotoR. BusteloX.R. Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis.EMBO J.20214022e10812510.15252/embj.202110812534617326
     [Google Scholar]
  12. SalaymehY. FaragoM. SebbanS. ShalomB. PikarskyE. KatzavS. Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice.Life Sci. Alliance202035e20200066110.26508/lsa.20200066132277014
     [Google Scholar]
  13. SmaginaA.S. KulemzinS.V. YusubalievaG.M. KedrovaA.G. SanzharovA.E. IvanovY.V. MatvienkoD.A. KalsinV.A. GorchakovA.A. BaklaushevV.P. TaraninA.V. VAV1-overexpressing YT cells display improved cytotoxicity against malignant cells.Biotechnol. Appl. Biochem.202168484985510.1002/bab.200132767384
     [Google Scholar]
  14. Fernandez-ZapicoM.E. Gonzalez-PazN.C. WeissE. SavoyD.N. MolinaJ.R. FonsecaR. SmyrkT.C. ChariS.T. UrrutiaR. BilladeauD.D. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis.Cancer Cell200571394910.1016/j.ccr.2004.11.02415652748
     [Google Scholar]
  15. LazerG. IdelchukY. SchapiraV. PikarskyE. KatzavS. The haematopoietic specific signal transducer Vav1 is aberrantly expressed in lung cancer and plays a role in tumourigenesis.J. Pathol.20092191253410.1002/path.257919533802
     [Google Scholar]
  16. GarciaJ.L. CouceiroJ. Gomez-MoretaJ.A. Gonzalez ValeroJ.M. BrizA.S. SauzeauV. LumbrerasE. DelgadoM. RobledoC. AlmuniaM.L. BusteloX.R. HernandezJ.M. Expression of VAV1 in the tumour microenvironment of glioblastoma multiforme.J. Neurooncol.20121101697710.1007/s11060‑012‑0936‑y22864683
     [Google Scholar]
  17. WakahashiS. SudoT. OkaN. UenoS. YamaguchiS. FujiwaraK. OhbayashiC. NishimuraR. VAV1 represses E-cadherin expression through the transactivation of Snail and Slug: a potential mechanism for aberrant epithelial to mesenchymal transition in human epithelial ovarian cancer.Transl. Res.2013162318119010.1016/j.trsl.2013.06.00523856093
     [Google Scholar]
  18. ZhuX. JinH. XiaZ. WuX. YangM. ZhangH. ShangX. ChengR. ZhanZ. YuZ. Vav1 expression is increased in esophageal squamous cell carcinoma and indicates poor prognosis.Biochem. Biophys. Res. Commun.2017486257157610.1016/j.bbrc.2017.03.09128336434
     [Google Scholar]
  19. TanD.J.H. NgC.H. LinS.Y. PanX.H. TayP. LimW.H. TengM. SynN. LimG. YongJ.N. QuekJ. XiaoJ. DanY.Y. SiddiquiM.S. SanyalA.J. MuthiahM.D. LoombaR. HuangD.Q. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.Lancet Oncol.202223452153010.1016/S1470‑2045(22)00078‑X35255263
     [Google Scholar]
  20. WenP. WangR. XingY. OuyangW. YuanY. ZhangS. LiuY. PengZ. The prognostic value of the GPAT/AGPAT gene family in hepatocellular carcinoma and its role in the tumor immune microenvironment.Front. Immunol.202314102666910.3389/fimmu.2023.102666936845084
     [Google Scholar]
  21. HornsteinI. PikarskyE. GroysmanM. AmirG. Peylan-RamuN. KatzavS. The haematopoietic specific signal transducer Vav1 is expressed in a subset of human neuroblastomas.J. Pathol.2003199452653310.1002/path.131412635144
     [Google Scholar]
  22. SebbanS. FaragoM. GashaiD. IlanL. PikarskyE. Ben-PorathI. KatzavS. Vav1 fine tunes p53 control of apoptosis versus proliferation in breast cancer.PLoS One201381e5432110.1371/journal.pone.005432123342133
     [Google Scholar]
  23. KangL. HaoX. TangY. ZhaoZ. ZhangH. GongY. Elevated level of Vav1 was correlated with advanced biological behavior and poor prognosis in patients with gastric cancer.Int. J. Clin. Exp. Pathol.201811139139831938123
     [Google Scholar]
  24. QiY. KongF.M. DengQ. LiJ.Y. CuiR. PuY.D. ZhaiQ.L. JiaY.J. LiY.M. Clinical significance and prognostic value of Vav1 expression in Non-small cell lung cancer.Am. J. Cancer Res.2015582491249726396925
     [Google Scholar]
/content/journals/ppl/10.2174/0109298665330781240830042601
Loading
Association between Higher Expression of Vav1 in Hepatocellular Carcinoma and Unfavourable Clinicopathological Features and Prognosis
PPL 31, 706 (2024); https://doi.org/10.2174/0109298665330781240830042601
/content/journals/ppl/10.2174/0109298665330781240830042601
/content/journals/ppl/10.2174/0109298665330781240830042601
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Hepatocellular carcinoma; immunohistochemistry; prognosis; survival analysis; tumour differentiation; vav1 protein

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test